UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2227-5
Program Prior Authorization/Medical Necessity
Medication Upneeq® (oxymetazoline) 0.1% ophthalmic solution
P&T Approval Date 12/2020, 12/2021, 12/2022, 12/2023, 12/2024
Effective Date 3/1/2025
1. Background:
Upneeq (oxymetazoline) 0.1% ophthalmic solution is indicated for the treatment of acquired
blepharoptosis in adults.
Coverage will be provided for members who meet the following criteria.
2. Coverage Criteriaa:
A. Initial Authorization
1. Upneeq will be approved based on ALL of the following criteria:
a. Diagnosis of acquired blepharoptosis
-AND-
b. Patient has a functional impairment related to the position of the eyelid
-AND-
c. One of the following:
1) Marginal reflex distance-1 (MRD-1) is less than or equal to 2 mm in primary
gaze
2) Marginal reflex distance-1 (MRD-1) is less than or equal to 2 mm in down gaze
3) Superior visual field loss of at least 12 degrees or 24 percent
-AND-
d. Other treatable causes of blepharoptosis have been ruled out (e.g., recent botulinum
toxin injections, myasthenia gravis)
-AND-
e. Prescribed by or in consultation with one of the following:
1) Optometrist
© 2024 UnitedHealthcare Services, Inc.
1
2) Ophthalmologist
Authorization will be issued for 12 months.
B. Reauthorization
1. Upneeq will be approved based on the following criterion:
a. Documentation of positive clinical response to therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
4. References:
1. Upneeq [package insert]. Bridgewater, NJ: RVL Pharmaceuticals, Inc; May 2023.
2. Charles B. Slonim, MD; Shane Foster, OD; Mark Jaros, PhD;, et. al. Association of
Oxymetazoline Hydrochloride, 0.1% Solution Administration with Visual Field in
Acquired Ptosis A Pooled Analysis of 2 Randomized Clinical Trials. JAMA Ophthalmol.
October 2020.
Program Prior Authorization/Medical Necessity – Upneeq
Change Control
12/2020 New program
12/2021 Annual review. Updated references.
12/2022 Annual review. Updated references.
12/2023 Annual review. Updated references.
12/2024 Annual review. Updated initial authorization to 12 months.
© 2024 UnitedHealthcare Services, Inc.
2